

REPLIGEN CORP  
Form 10-Q  
August 06, 2015  
[Table of Contents](#)

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 10-Q**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended June 30, 2015**

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission File Number 000-14656**

**REPLIGEN CORPORATION**  
**(Exact name of registrant as specified in its charter)**

<b>Delaware</b> <b>(State or other jurisdiction of</b>  <b>incorporation or organization)</b>  <b>41 Seyon Street, Bldg. 1, Suite 100</b>	<b>04-2729386</b> <b>(I.R.S. Employer</b>  <b>Identification No.)</b>  <b>02453</b> <b>(Zip Code)</b> <b>Registrant's telephone number, including area code: (781) 250-0111</b>
--	--

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Edgar Filing: REPLIGEN CORP - Form 10-Q

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☒

Accelerated filer ☐

Non-accelerated filer ☐ (Do not check if a smaller reporting company)

Smaller reporting company ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.): Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of July 31, 2015.

Class	Number of Shares
Common Stock, par value \$.01 per share	32,910,187

**Table of Contents**

**Table of Contents**

	<b>PAGE</b>
<b>PART I FINANCIAL INFORMATION</b>	
Item 1. Unaudited Condensed Consolidated Financial Statements	
<u>Condensed Consolidated Balance Sheets as of June 30, 2015 and December 31, 2014</u>	3
<u>Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three- and Six-Month Periods Ended June 30, 2015 and 2014</u>	4
<u>Condensed Consolidated Statements of Cash Flows for the Six-Month Periods Ended June 30, 2015 and 2014</u>	5
<u>Notes to Unaudited Condensed Consolidated Financial Statements</u>	6
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	21
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	26
Item 4. <u>Controls and Procedures</u>	26
<b>PART II. OTHER INFORMATION</b>	28
Item 1. <u>Legal Proceedings</u>	28
Item 1A. <u>Risk Factors</u>	28
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	28
Item 3. <u>Defaults Upon Senior Securities</u>	28
Item 4. <u>Mine Safety Disclosures</u>	28
Item 5. <u>Other Information</u>	28
Item 6. <u>Exhibits</u>	29
<u>Signatures</u>	30

**Table of Contents**

**REPLIGEN CORPORATION**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
**(Unaudited)**

	<b>June 30, 2015</b>	<b>December 31, 2014</b>
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 40,012,048	\$ 35,363,024
Marketable securities	23,154,820	23,090,209
Accounts receivable, less reserve for doubtful accounts of \$73,550 and \$40,644, respectively	14,419,602	7,760,382
Other receivables	523,369	239,890
Inventories	14,305,676	12,383,633
Deferred tax asset, net	4,928	4,928
Prepaid expenses and other current assets	846,808	2,103,576
Total current assets	93,267,251	80,945,642
Property, plant and equipment, at cost:		
Leasehold improvements	13,249,754	9,108,214
Equipment	13,526,113	13,115,630
Furniture and fixtures	2,651,661	2,270,347
Construction in progress	76,519	3,847,746
Total property, plant and equipment, at cost	29,504,047	28,341,937
Less: Accumulated depreciation	(15,040,331)	(13,815,697)
Property, plant and equipment, net	14,463,716	14,526,240
Long-term marketable securities	1,223,468	3,550,210
Intangible assets, net	13,594,163	14,636,307
Goodwill	14,346,057	14,184,835
Restricted cash	450,000	450,000
Total assets	\$ 137,344,655	\$ 128,293,234
<b>Liabilities and stockholders' equity</b>		
Current liabilities:		
Accounts payable	\$ 4,303,354	\$ 3,863,350
Accrued liabilities	11,522,317	6,819,063
Total current liabilities	15,825,671	10,682,413
Other long-term liabilities	3,296,446	5,879,013
Commitments and contingencies (Note 11)		

Stockholders' equity:

Preferred stock, \$.01 par value, 5,000,000 shares authorized, no shares issued or outstanding

Common stock, \$.01 par value, 80,000,000 shares authorized, 32,902,987 shares at June 30, 2015 and 32,774,374 shares at December 31, 2014 issued and outstanding

	329,030	327,744
Additional paid-in capital	200,435,716	198,064,414
Accumulated other comprehensive income (loss)	(8,197,044)	(5,773,142)
Accumulated deficit	(74,345,164)	(80,887,208)
Total stockholders' equity	118,222,538	111,731,808

Total liabilities and stockholders' equity	\$ 137,344,655	\$ 128,293,234
--	----------------	----------------

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Table of Contents****REPLIGEN CORPORATION****CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME****(Unaudited)**

	<b>Three months ended June 30,</b>		<b>Six months ended June 30,</b>	
	<b>2015</b>	<b>2014</b>	<b>2015</b>	<b>2014</b>
<b>Revenue:</b>				
Product revenue	\$ 21,457,267	\$ 15,551,077	\$ 42,273,543	\$ 29,885,764
Royalty and other revenue				1,991,166
Total revenue	21,457,267	15,551,077	42,273,543	31,876,930
<b>Operating expenses:</b>				
Cost of product revenue	8,586,147	6,671,581	16,659,051	13,006,645
Cost of royalty revenue				
Research and development	1,251,576	1,430,133	2,819,150	2,631,123
Selling, general and administrative	6,242,275	4,325,834	12,266,801	7,709,444
Contingent consideration fair value adjustments	768,556	17,700	1,880,930	116,020
Total operating expenses	16,848,554	12,445,248	33,625,932	23,463,232
Income from operations	4,608,713	3,105,829	8,647,611	8,413,698
Investment income	19,012	84,920	55,597	186,736
Interest expense	(7,788)	(12,780)	(16,829)	(26,865)
Other income (expense)	(268,549)	65,280	(136,518)	67,785
Income before income taxes	4,351,388	3,243,249	8,549,861	8,641,354
Income tax provision	738,831	417,827	2,007,817	1,538,829
Net income	\$ 3,612,557	\$ 2,825,422	\$ 6,542,044	\$ 7,102,525
<b>Earnings per share:</b>				
Basic	\$ 0.11	\$ 0.09	\$ 0.20	\$ 0.22
Diluted	\$ 0.11	\$ 0.09	\$ 0.19	\$ 0.22
<b>Weighted average shares outstanding:</b>				
Basic	32,870,473	32,233,694	32,827,536	32,098,269
Diluted	33,670,696	33,076,384	33,581,682	32,963,554
<b>Other comprehensive income:</b>				
Unrealized gain (loss) on investments	(4,962)	9,882	(22,331)	12,066
Foreign currency translation gain (loss)	1,447,038	(1,462,603)	(2,401,571)	(1,605,757)

Edgar Filing: REPLIGEN CORP - Form 10-Q

Comprehensive income	\$ 5,054,633	\$ 1,372,701	\$ 4,118,142	\$ 5,508,834
----------------------	--------------	--------------	--------------	--------------

The accompanying notes are an integral part of these condensed consolidated financial statements.



**Table of Contents**

**REPLIGEN CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(Unaudited)**

	<b>Six months ended June 30,</b>	
	<b>2015</b>	<b>2014</b>
Cash flows from operating activities:		
Net income:	\$ 6,542,044	\$ 7,102,525
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	2,295,569	1,855,392
Stock-based compensation expense	1,686,926	852,637
Deferred tax expense	173,105	153,704
Loss on revaluation of contingent consideration	1,880,930	116,020
Loss on disposal of assets	1,156	2,640
Bad debt reserve	32,902	
Changes in assets and liabilities:		
Accounts receivable	(6,853,392)	(2,547,815)
Other receivables	(283,478)	6,354,278
Inventories	(2,380,129)	(286,261)
Prepaid expenses and other current assets	981,580	(300,432)
Accounts payable	586,581	2,069,947
Accrued liabilities	874,652	(4,844,919)
Long-term liabilities	(425,413)	(207,390)
Net cash provided by operating activities	5,113,034	10,320,326
Cash flows from investing activities:		
Purchases of marketable securities	(8,118,938)	(18,635,241)
Redemptions of marketable securities	10,358,735	24,491,993
Acquisition of assets of Refine Technology, LLC		(21,235,937)
Increase in restricted cash		(250,000)
Purchases of property, plant and equipment	(1,736,695)	(1,224,091)
Net cash provided by (used in) investing activities	503,102	(16,853,276)
Cash flows from financing activities:		
Exercise of stock options	685,661	1,337,906
Payment of contingent considerations	(99,000)	
Net cash provided by financing activities	586,661	1,337,906
Effect of exchange rate changes on cash and cash equivalents	(1,553,773)	(878,891)
Net increase (decrease) in cash and cash equivalents	4,649,024	(6,073,935)

Edgar Filing: REPLIGEN CORP - Form 10-Q

Cash and cash equivalents, beginning of period	35,363,024	39,829,653
Cash and cash equivalents, end of period	\$ 40,012,048	\$ 33,755,718
Supplemental disclosure of non-cash investing activities:		
Income taxes paid	\$ 1,629,000	\$ 668,000

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Table of Contents**

**REPLIGEN CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Unaudited)**

**1. Basis of Presentation**

The consolidated financial statements included herein have been prepared by Repligen Corporation (the "Company," "Repligen" or "we") in accordance with generally accepted accounting principles in the United States ("U.S. GAAP") and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by U.S. GAAP. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014.

In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

***Recently Issued Accounting Pronouncements***

In May 2014, the FASB issued ASU No. 2014-09, which amends the guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification Topic 605, *Revenue Recognition*, and creates a new Topic 606, *Revenue from Contracts with Customers*. This guidance is expected to be effective for fiscal years beginning after December 15, 2017, with early adoption permitted in fiscal years beginning after December 15, 2016. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. The Company has not yet determined which adoption method it will utilize or the effect that the adoption of this guidance will have on its consolidated financial statements.

In July 2015, the FASB issued ASU 2015-11, "Simplifying the Measurement of Inventory," ("ASU 2015-11"). ASU 2015-11 requires inventory be measured at the lower of cost and net realizable value and options that currently exist for market value be eliminated. ASU 2015-11 defines net realizable value as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective prospectively for reporting periods beginning after December 15, 2016 and interim periods within those fiscal years with early adoption permitted. The Company does not expect the adoption of ASU 2015-11 to have a material impact on its consolidated financial statements.

## **2. Acquisitions, Goodwill and Other Intangible Assets**

### ***Acquisition of Refine Technology, LLC***

On June 2, 2014, pursuant to the terms of the Asset Purchase Agreement, dated as of June 2, 2014 (the "Asset Purchase Agreement"), by and among the Company, Refine Technology, LLC (a limited liability company formed under the laws of the State of New Jersey) ("Refine"), the members of Refine, Jerry Shevitz, Refine Technology Sales LLC (a limited liability company formed under the laws of the State of New Jersey) and Refine Technology Sales Asia PTE. LTD. (a limited private company organized in the Republic of Singapore), the Company acquired the business of Refine, including Refine's Alternating Tangential Flow ("ATF") System, a market-leading device used to significantly increase product yield during the fermentation step of the biologic drug manufacturing process (the "Refine Business" and the acquisition of the Refine Business, the "Refine Acquisition"). Pursuant to the Asset Purchase Agreement, Repligen purchased all of the assets related to Refine's ATF system and assumed certain specified liabilities related to Refine's ATF system. This acquisition strengthened Repligen's bioprocessing business by adding a complementary product line while expanding its direct sales presence worldwide. The transaction was accounted for as a purchase of a business under ASC 805, Business Combinations. The terms of the acquisition included an upfront cash payment of \$21,235,937 less \$66,277 as a result of the final determination of working capital, issuance of 215,285 shares of the Company's \$0.01 par value common stock valued at \$4,000,000, potential milestone payments totaling up to \$10,900,000 for the achievement of specific sales targets in the years 2014, 2015 and 2016, and future potential payments up to \$7,500,000 out of any amounts that might be received in connection with the resolution, withdrawal or settlement of certain patent disputes with a third party. During the six months ended June 30, 2015, the

**Table of Contents**

Company paid Refine a \$1,000,000 milestone payment for achievement of the 2014 sales target under the Asset Purchase Agreement. The \$10,900,000 contingent consideration had an initial probability weighted fair value at acquisition of \$1,370,000. The \$7,500,000 contingent consideration had only a nominal probability weighted fair value at acquisition. In addition to the initial consideration, approximately \$774,000 was paid to Refine following the acquisition under a Transition Services Agreement under which certain employees of Refine provided services to the Company for up to six months in support of the Refine Business. As these payments were contingent upon future service, they were recognized ratably as operating expense while the services were provided.

*Consideration Transferred*

The Company accounted for the Refine Acquisition as the purchase of a business under U.S. GAAP. Under the acquisition method of accounting, the assets of the Refine Business were recorded as of the acquisition date, at their respective fair values, and consolidated with those of Repligen. The fair value of the net assets acquired was approximately \$26,539,660.

The preparation of the valuation required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable. However, actual results may differ from these estimates.

The total consideration transferred follows:

Cash consideration,	\$ 21,169,660
Value of common stock issued	4,000,000
Estimated fair value of contingent consideration	1,370,000
 Total consideration transferred	 \$ 26,539,660

The fair value of contingent consideration was determined based upon a probability weighted analysis of expected future payments to be made to the seller. The Company paid to Refine \$1,000,000 during the six months ended June 30, 2015 for achievements of sales targets met in 2014, and could make payments of up to \$9,900,000 if specific sales targets are met for years 2015 and 2016. In addition, the Company could pay Refine up to \$7,500,000 out of any receipts that might be received in connection with the resolution, withdrawal or settlement of certain patent disputes with a third party. The liability for contingent consideration is included in current liabilities on the consolidated balance sheets and will be remeasured at each reporting period until the contingency is resolved. Please see Note 8 - Fair Value Measurement for further details.

Acquisition related costs are not included as a component of consideration transferred, but are expensed in the periods in which the costs are incurred. The Company incurred approximately \$817,835 in transaction costs related to the Refine Acquisition. The transaction costs are included in 2014 selling, general and administrative expenses in the consolidated statements of comprehensive income.

*Fair Value of Net Assets Acquired*

The allocation of purchase price was based on the fair value of assets acquired and liabilities assumed as of June 2, 2014. The components and allocation of the purchase price consists of the following amounts:

Accounts receivable	\$ 1,646,746
Inventory	1,003,422
Other current assets	184,080
Fixed assets	84,662
Customer relationships	6,400,000
Developed technology	2,000,000
In process research and development ( IPR&D )	1,600,000
Trademark and trade name	700,000
Accounts payable and other liabilities assumed	(431,307)
Goodwill	13,352,057
Net assets acquired	\$ 26,539,660

Of the consideration paid, \$6,400,000 represents the fair value of customer relationships that will be amortized over the determined useful life of 10 years, and \$2,000,000 represents the fair value of developed technology that will be amortized over a determined useful life of 15 years. \$700,000 represents the fair value of trademark and trade name determined to have an indefinite useful life and is not subject to amortization.

**Table of Contents**

\$1,600,000 of the consideration paid represents the fair value of acquired IPR&D projects that are considered identifiable assets as of the acquisition date. Those assets are considered indefinite lived until efforts associated with the projects are completed or abandoned. The major acquired technology IPR&D relates to the development of a single use system product extension to the ATF system business. The IPR&D project assets are not currently amortized and are reviewed for impairment at least annually. There was no evidence of impairment to IPR&D as of June 30, 2015. The excess of the purchase price over the fair value of tangible and intangible assets acquired was recorded to goodwill. The goodwill recognized is attributable to expected synergies that the Company will realize from this acquisition. This goodwill is deductible for tax purposes over 15 years from the date of acquisition.

*Revenue, Net Income and Pro Forma Presentation*

The Company recorded revenue from Refine of \$466,000 from June 2, 2014 through June 30, 2014 and \$5,394,000 for the six-month period ended June 30, 2015. The segregation of Refine's net income is administratively impractical, as the Company operates as one operating segment and does not separately allocate expenses. The Company has included the operating results of Refine in its consolidated statements of operations since the June 2, 2014 acquisition date. The following table presents unaudited supplemental pro forma information as if the Refine Acquisition had occurred as of January 1, 2014.

	<b>Three Months ended June 30,</b>		<b>Six Months ended June 30,</b>	
	<b>(in thousands)</b>		<b>(in thousands)</b>	
	<b>2015</b>	<b>2014</b>	<b>2015</b>	<b>2014</b>
Total revenue	\$ 21,457	\$ 17,707	\$ 42,274	\$ 35,659

The unaudited pro forma information for the three- and six-month periods ended June 30, 2015 and 2014 was calculated after applying the Company's accounting policies and the impact of acquisition date fair value adjustments.

*Other Intangible Assets*

Intangible assets, except for the Refine Technology, LLC tradename and in-process research and development, are amortized over their useful lives using the estimated economic benefit method, as applicable, and the amortization expense is recorded within selling, general and administrative expense in the Company's statements of comprehensive income. The Refine Technology, LLC tradename and in-process research and development are not amortized. The Company reviews its indefinite-lived intangible assets not subject to amortization to determine if adverse conditions exist or a change in circumstances exists that would indicate an impairment. Intangible assets and their related useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. More frequent impairment assessments are conducted if certain conditions exist, including a change in the Company's competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for its products or changes in the size of the market for its products. An impairment results if the carrying value of the asset exceeds the estimated fair value of the asset. If the estimate of an intangible asset's remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. The Company continues to believe that its intangible assets are recoverable at June 30, 2015.

Other intangible assets consisted of the following at June 30, 2015:

	<b>Gross Carrying Amount</b>	<b>Accumulated Amortization</b>	<b>Weighted Average Useful Life (in years)</b>
Technology developed	\$ 3,301,656	\$ (883,188)	12
In process research and development	1,600,000		
Patents	240,000	(162,500)	8
Customer relationships	11,867,405	(3,069,210)	9
Trademark/ tradename	700,000		
 Total other intangible assets	 \$ 17,709,061	 \$ (4,114,898)	 10



**Table of Contents**

Other intangible assets consisted of the following at December 31, 2014:

	<b>Gross Carrying Amount</b>	<b>Accumulated Amortization</b>	<b>Weighted Average Useful Life (in years)</b>
Technology developed	\$ 3,337,658	\$ (750,066)	12
In process research and development	1,600,000		
Patents	240,000	(147,500)	8
Customer relationships	12,202,219	(2,546,004)	9
Trademark/ tradename	700,000		
<b>Total other intangible assets</b>	<b>\$ 18,079,877</b>	<b>\$ (3,443,570)</b>	<b>10</b>

Amortization expense for amortized intangible assets was approximately \$801,000 for the six-month period ended June 30, 2015. In each of the next five years, the Company expects to record amortization expense of:

<b>Years Ending</b>	<b>Amortization Expense</b>
December 31, 2015 (six months remaining)	\$ 845,000
December 31, 2016	1,707,000
December 31, 2017	1,707,000
December 31, 2018	1,543,000
December 31, 2019	1,528,000
December 31, 2020	1,204,000

**3. Revenue Recognition***Product Sales*

The Company's revenue recognition policy is to recognize revenues from product sales and services in accordance with ASC 605, *Revenue Recognition*. These standards require that revenues are recognized when persuasive evidence of an arrangement exists, product delivery, including customer acceptance, has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Determination of whether these criteria have been met are based on management's judgments primarily regarding the fixed nature of the fee charged for the product delivered and the collectability of those fees. The Company has a few longstanding customers who comprise the majority of revenue and have excellent payment histories and therefore the Company does not require collateral. The Company has had no significant write-offs of uncollectible invoices in the periods presented. When more than one element such as equipment, consumables, and services are contained in a single arrangement, the Company allocates revenue among the elements based on each element's relative selling price, provided that each element meets the criteria for treatment as a separate unit of accounting. An item is considered a separate unit of accounting if it has value to the customer on a stand-alone basis. The selling price of the undelivered elements is determined by the price charged when the element is sold separately, or in cases when the item is not sold separately, by third-party evidence of selling price or management's best estimate of selling price.

The Company's product revenues are from the sale of bioprocessing products, equipment devices, and related consumables used with these equipment devices to customers in the life science and biopharmaceutical industries. For product sales to end customers, revenue is recognized, net of discounts, when both the title and risk of loss have transferred to the customer, as determined by the shipping terms, provided there are no uncertainties regarding acceptance, and all obligations have been completed. Generally, the Company's product arrangements for equipment sales are multiple element arrangements, and may include services, such as installation and training, and multiple products, such as consumables and spare parts. In accordance with ASC 605-25, based on the terms and conditions of the product arrangements, the Company believes that these services and undelivered products can be accounted for separately from the delivered product element, as the delivered products have value to the Company's customers on a stand-alone basis. Accordingly, revenue for services not yet performed at the time of product shipment are deferred and recognized as such services are performed. The relative selling price of any undelivered products is also deferred at the time of shipment and recognized as revenue when these products are delivered. For product sales to distributors, the Company recognizes revenue for both equipment and consumables upon delivery to the distributor unless direct shipment to the end user is requested. In this case, revenue is recognized upon delivery to the end user's location. In general, distributors are responsible for shipment to the end customer along with installation, training and acceptance of the equipment by the end customer. Sales to distributors are not contingent upon resale of the product.

## **Table of Contents**

At the time of sale, the Company also evaluates the need to accrue for warranty and sales returns. The supply agreements the Company has with its customers and the related purchase orders identify the terms and conditions of each sale and the price of the goods ordered. Due to the nature of the sales arrangements, inventory produced for sale is tested for quality specifications prior to shipment. Since the product is manufactured to order and in compliance with required specifications prior to shipment, the likelihood of sales returns, warranty or other issues is largely diminished. Furthermore, there is no customer right of return in the Company's sales agreements. Sales returns and warranty issues are infrequent and have had nominal impact on the Company's financial statements historically.

### *Therapeutics Licensing Agreements*

Activities under licensing agreements are evaluated in accordance with ASC 605-25 to determine if they represent a multiple element revenue arrangement. The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting. The Company accounts for those components as separate units of accounting if the following two criteria are met:

The delivered item or items have value to the customer on a stand-alone basis.

If there is a general right of return relative to the delivered items, delivery or performance of the undelivered items is considered probable and within the Company's control.

Factors considered in this determination include, among other things, whether any other vendors sell the items separately and if the licensee could use the delivered item for its intended purpose without the receipt of the remaining deliverables. If multiple deliverables included in an arrangement are separable into different units of accounting, the Company allocates the arrangement consideration to those units of accounting. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative selling price. Revenue is recognized for each unit of accounting when the appropriate revenue recognition criteria are met.

Future milestone payments, if any, under a license agreement will be recognized under the provisions of ASC 605-28, which the Company adopted on January 1, 2011. The Company has elected to recognize a payment that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is substantive if:

It can only be achieved based in whole or in part on either the Company's performance or the occurrence of a specific outcome resulting from the Company's performance;

There is substantive uncertainty at the date an arrangement is entered into that the event will be achieved; and

It would result in additional payments being due to the entity.

The commercial milestone payments and royalty payments received under license agreements, if any, will be recognized as revenue when they are earned.

*Sale of Intellectual Property to BioMarin*

In January 2014, the Company entered into an asset purchase agreement (the BioMarin Asset Purchase Agreement ) with BioMarin Pharmaceutical Inc. ( BioMarin ) to sell the Company s histone deacetylase inhibitor (HDACi) portfolio. Pursuant to the terms of the BioMarin Asset Purchase Agreement, the Company received \$2 million from BioMarin as an upfront payment on January 30, 2014 and a \$125,675 payment on September 3, 2014 upon completion of the Technology Transfer. The Company is entitled to receive up to \$160 million in potential future milestone payments for the development, regulatory approval and commercial sale of portfolio compounds included in the agreement. These potential milestone payments are approximately 37% related to clinical development and 63% related to initial commercial sales in specific geographies. In addition, the Company is eligible to receive royalties on sales of therapeutic products originating from the HDACi portfolio. The royalty rates are tiered and begin in the mid-single-digits for the first HDACi portfolio product and for the first non-HDACi portfolio product with lesser amounts for any backup products developed under the BioMarin Asset Purchase Agreement. The Company s receipt of these royalties is subject to customary offsets and deductions. There are no refund provisions in this agreement. The Company recognized \$2.1 million of revenue in the fiscal year ended December 31, 2014, related to the transfer of the HDACi technology under the BioMarin Asset Purchase Agreement. The Company did not recognize any revenue in the three- and six-month periods ended June 30, 2015. Any milestones earned upon specified clinical development or commercial sales events or future royalty payments under the BioMarin Asset Purchase Agreement will be recognized as revenue when they are earned.

## **Table of Contents**

Activities under this agreement were evaluated in accordance with ASC 605-25 to determine if they represented a multiple element revenue arrangement. The Company identified the following deliverables in the BioMarin Asset Purchase Agreement:

The assignment by the Company to BioMarin of the Repligen Technology ( Repligen Know-How and Repligen Patents ) and the Scripps Agreement (the Transferred Assets );

The transfer of certain notebooks, data, documents, biological materials (if any) and other such documents in the Company's possession that might be useful to further development of the program (the Technology Transfer ).

Two criteria must be met in order for a deliverable to be considered a separate unit of accounting. The first criterion requires that the delivered item or items have value to the customer on a stand-alone basis. The second criterion, which relates to evaluating a general right of return, is not applicable because such a provision does not exist in the BioMarin Asset Purchase Agreement. The deliverables outlined above were deemed to have stand-alone value and to meet the criteria to be accounted for as separate units of accounting. Factors considered in this determination included, among other things, BioMarin's right under the agreement to assign the Transferred Assets, whether any other vendors sell the items separately and if BioMarin could use the delivered item for its intended purpose without the receipt of the remaining deliverables. If multiple deliverables included in an arrangement are separable into different units of accounting, the multiple-element arrangements guidance addresses how to allocate the arrangement consideration to those units of accounting. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. Arrangement consideration is allocated at the inception of the arrangement to the identified units of accounting based on their relative selling price.

The Company identified the arrangement consideration to allocate among the units of accounting as the \$2.0 million non-refundable up-front payment and the \$125,675 payment to be received upon completion of the Technology Transfer. The Company excluded the potential milestone payments provided for in the BioMarin Asset Purchase Agreement from the arrangement consideration, as they were not considered fixed or determinable at the time the BioMarin Asset Purchase Agreement was signed. Because the Company had not sold these items on a stand-alone basis previously, it had no vendor-specific objective evidence of selling price. Furthermore, the Company did not have detailed third-party evidence of selling price, and as a result the Company used its best estimate of selling price for each item. In determining these prices, the Company considered what it would be willing to sell the items for on a stand-alone basis, what the market would bear for such items and what another party might charge for these items.

The up-front arrangement consideration allocated to the Transferred Assets was recognized upon execution of the BioMarin Asset Purchase Agreement as the risks and rewards associated with the Transferred Assets transferred at that time. The Company used a discounted cash flow analysis to determine the value of the Transferred Assets. Key assumptions in the analysis included: the estimated market size for a compound targeted at Friedreich's Ataxia, the estimated remaining costs of development and time to commercialization, and the probability of successfully developing and commercializing the program. Based on this analysis, the Company allocated \$2,115,000 to the value of the Transferred Assets. However, as the recognized revenue is limited to the non-contingent consideration received, the Company recognized approximately \$2,000,000, the amount of the up-front payment, as revenue in the first quarter of 2014.

The estimated selling price of the Technology Transfer items was approximately \$300,000, resulting in consideration allocation of approximately \$11,000. However, as this item was not delivered prior to June 30, 2014, the Company did

not recognize any revenue related to the Technology Transfer in the six months ended June 30, 2014. Repligen received the payment and recognized \$125,675 of other revenues in September 2014 upon completion of the Technology Transfer. The Company believes that a change in the key assumptions used to determine best estimate of selling price for each of the deliverables would not have a significant effect on the allocation of arrangement consideration.

In addition to the \$2.1 million up-front payment, the Company is also eligible to receive up to \$160 million in potential milestone payments from BioMarin comprised of:

Up to \$60 million related to the achievement of specified clinical and regulatory milestone events; and

Up to \$100 million related to the achievement of specified commercial sales events, specifically the first commercial sale in specific territories.

The Company evaluated the potential milestones in accordance with ASC 605-28, which allows an entity to make an accounting policy election to recognize a payment that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. This evaluation included an assessment of the risks that must be overcome to achieve the respective milestone as well as whether the achievement of the milestone was due in part to the Company's initial clinical work, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met.

**Table of Contents**

The Company believes that the \$60 million of specified clinical and regulatory milestone payments are substantive. Therefore, any such milestones achieved will be recognized as revenue when earned.

Any milestones achieved upon specified commercial sales events or future royalty payments are considered contingent revenue under the BioMarin Asset Purchase Agreement, and will be recognized as revenue when they are earned as there are no undelivered elements remaining and no continuing performance obligations under the arrangement.

**4. Accumulated Other Comprehensive Income**

The following table summarizes the changes in accumulated other comprehensive income by component:

(In thousands)	Unrealized gain (loss) on investments	Foreign currency translation gain (loss)	Total
Balance at December 31, 2014	\$ (33,054)	\$ (5,740,088)	\$ (5,773,142)
Other comprehensive income/(loss) before reclassifications	(22,331)	(2,401,571)	(2,423,902)
Amounts reclassified from accumulated other comprehensive income			
Net current period other comprehensive income/(loss)	(22,331)	(2,401,571)	(2,423,902)
Balance at June 30, 2015	\$ (55,385)	\$ (8,141,659)	\$ (8,197,044)

**5. Earnings Per Share**

The Company reports earnings per share in accordance with Accounting Standards Codification Topic 260, *Earnings Per Share*, which establishes standards for computing and presenting earnings per share. Basic earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of common shares and dilutive common share equivalents then outstanding. Potential common share equivalents consist of restricted stock awards and the incremental common shares issuable upon the exercise of stock options. Under the treasury stock method, unexercised in-the-money stock options and warrants are assumed to be exercised at the beginning of the period or at issuance, if later. The assumed proceeds are then used to purchase common shares at the average market price during the period. Share-based payment awards that entitle their holders to receive non-forfeitable dividends before vesting are considered participating securities and are considered in the calculation of basic and diluted earnings per share.

Basic and diluted weighted average shares outstanding were as follows:

	<b>Three months ended June 30,</b>		<b>Six months ended June 30,</b>	
	<b>2015</b>	<b>2014</b>	<b>2015</b>	<b>2014</b>
Weighted average common shares	32,870,473	32,233,694	32,827,536	32,098,269
Dilutive common stock options	800,223	842,690	754,146	865,285
Weighted average common shares, assuming dilution	33,670,696	33,076,384	33,581,682	32,963,554

At June 30, 2015, there were outstanding options to purchase 1,265,486 shares of the Company's common stock at a weighted average exercise price of \$9.68 per share. For the three- and six-month periods ended June 30, 2015, 126,541 and 150,041 shares of the Company's common stock, respectively, were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares, and were therefore anti-dilutive.

At June 30, 2014, there were outstanding options to purchase 1,312,741 shares of the Company's common stock at a weighted average exercise price of \$7.19 per share. For the three- and six-month periods ended June 30, 2014, 264,317 and 300,908 shares of the Company's common stock, respectively, were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares, and were therefore anti-dilutive.



**Table of Contents****6. Stock-Based Compensation**

For the three months ended June 30, 2015 and 2014, the Company recorded stock-based compensation expense of \$984,944 and \$545,212, respectively, for share-based awards granted under the Second Amended and Restated 2001 Repligen Corporation Stock Plan (the 2001 Plan ) and the Repligen Corporation Amended and Restated 2012 Stock Option and Incentive Plan (the 2012 Plan, and collectively with the 2001 Plan and the 1992 Repligen Corporation Stock Option Plan, the Plans ). The Company recorded stock-based compensation expense of \$1,686,926 and \$852,637 for the six-month periods ended June 30, 2015 and 2014, respectively, for share-based awards granted under the Plans.

The following table presents stock-based compensation expense included in the Company's consolidated statements of comprehensive income:

	<b>Three months ended June 30,</b>		<b>Six months ended June 30,</b>	
	<b>2015</b>	<b>2014</b>	<b>2015</b>	<b>2014</b>
Cost of product revenue	\$ 63,068	\$ 63,285	\$ 105,975	\$ 89,848
Research and development	89,905	80,392	159,177	111,995
Selling, general and administrative	831,971	401,535	1,421,774	650,794
Total	\$ 984,944	\$ 545,212	\$ 1,686,926	\$ 852,637

The 2012 Plan allows for the granting of incentive and nonqualified options to purchase shares of common stock, restricted stock, restricted stock units and other equity awards. Incentive options and restricted stock units granted to employees under the Plans generally vest over a three to five-year period, with 20%-33% vesting on the first anniversary of the date of grant and the remainder vesting in equal yearly installments thereafter. Nonqualified options issued to non-employee directors under the Plans generally vest over one year. Options granted under the Plans have a maximum term of ten years from the date of grant and generally, the exercise price of the stock options equals the fair market value of the Company's common stock on the date of grant. At June 30, 2015, options to purchase 1,265,486 shares were outstanding under the Plans. At June 30, 2015, 2,490,973 shares were available for future grant under the 2012 Plan.

The Company uses the Black-Scholes option pricing model to calculate the fair value of share-based awards on the grant date. The Company measures stock-based compensation cost at the grant date based on the estimated fair value of the award and recognizes awards with service based vesting as expense over the employee's requisite service period on a straight-line basis. The Company records the expense for share-based awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates whether the achievement of a performance-based milestone is probable as of the reporting date. The Company has no awards that are subject to performance or market conditions as of June 30, 2015. The Company recognizes stock-based compensation expense for options that are ultimately expected to vest, and accordingly, such compensation expense has been adjusted for estimated forfeitures.

**Table of Contents**

Information regarding option activity for the six months ended June 30, 2015 under the Plans is summarized below:

	<b>Options Outstanding</b>	<b>Weighted- Average Exercise Price Per Share</b>	<b>Weighted- Average Remaining Contractual Term (in years)</b>	<b>Aggregate Intrinsic Value</b>
Options outstanding at January 1, 2015	1,225,117	\$ 8.31		
Granted	224,182	14.31		
Exercised	(128,613)	5.03		
Forfeited/Cancelled	(55,200)	8.96		
Options outstanding at June 30, 2015	1,265,486	\$ 9.68	7.23	\$ 39,977,638
Options exercisable at June 30, 2015	466,706	\$ 6.21	5.01	\$ 16,360,523
Vested and expected to vest at June 30, 2015 (1)	1,184,234	\$ 9.68	7.19	\$ 37,410,229

- (1) Represents the number of vested options as of June 30, 2015 plus the number of unvested options expected to vest as of June 30, 2015 based on the unvested outstanding options at June 30, 2015 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the closing price of the common stock on June 30, 2015 of \$41.27 and the exercise price of each in-the-money option) that would have been received by the option holders had all option holders exercised their options on June 30, 2015.

The weighted average grant date fair value of options granted during the six months ended June 30, 2015 and 2014 was \$21.83 and \$10.85, respectively. The total fair value of stock options that vested during the six months ended June 30, 2015 and 2014 was approximately \$1,521,511 and \$646,322, respectively.

As of June 30, 2015, there was \$7,318,939 of total unrecognized compensation cost related to unvested share-based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 2.97 years. The Company expects 717,528 unvested options to vest over the next five years.

## 7. Cash, Cash Equivalents and Marketable Securities

At June 30, 2015 and December 31, 2014, the Company's investments included money market funds as well as short-term and long-term marketable securities. These marketable securities are classified as available-for-sale. Marketable securities are investments with original maturities of greater than 90 days. Long-term marketable securities are securities with maturities of greater than one year. The average remaining contractual maturity of marketable securities at June 30, 2015 is approximately 5.75 months.

Management reviewed the Company's investments as of June 30, 2015 and December 31, 2014 and concluded that there are no securities with other than temporary impairments in its investment portfolio. The Company does not intend to sell any investments in an unrealized loss position, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases.

**Table of Contents**

Investments in money market funds and marketable securities consisted of the following at June 30, 2015:

		<b>June 30, 2015</b>		
	<b>Amortized</b>	<b>Gross</b>	<b>Gross</b>	
	<b>Cost</b>	<b>Unrealized</b>	<b>Unrealized</b>	<b>Fair Value</b>
		<b>Gain</b>	<b>Loss</b>	
Marketable securities:				
U.S. Government and agency securities	\$ 12,092,702	\$ 4,006	\$ (349)	\$ 12,092,359
Corporate and other debt securities	11,060,445	1,394	(3,378)	11,058,461
	23,153,147	5,400	(3,727)	23,154,820
Long-term marketable securities:				
U.S. Government and agency securities	1,223,276	272	(80)	1,223,468
Corporate and other debt securities				
	1,223,276	272	(80)	1,223,468
<b>Total</b>	<b>\$ 24,376,423</b>	<b>\$ 5,672</b>	<b>\$ (3,807)</b>	<b>\$ 24,378,288</b>

At June 30, 2015, the Company's investments included twenty-six securities in unrealized loss positions with a total unrealized loss of approximately \$4,000 and a total fair market value of approximately \$10,144,000. All investments with gross unrealized losses have been in unrealized loss positions for less than 12 months. The unrealized losses were caused primarily by current economic and market conditions. There was no change in the credit risk of the securities. There were no realized gains or losses on the investments for the six months ended June 30, 2015 or the six months ended June 30, 2014.

Investments in money market funds and marketable securities consisted of the following at December 31, 2014:

		<b>December 31, 2014</b>		
	<b>Amortized</b>	<b>Gross</b>	<b>Gross</b>	
	<b>Cost</b>	<b>Unrealized</b>	<b>Unrealized</b>	<b>Fair Value</b>
		<b>Gain</b>	<b>Loss</b>	
Marketable securities:				
U.S. Government and agency securities	\$ 12,716,167	\$ 2,174	\$ (2,072)	\$ 12,716,269
Corporate and other debt securities	10,373,332	4,229	(3,621)	10,373,940
	23,089,499	6,403	(5,693)	23,090,209
Long-term marketable securities:				
U.S. Government and agency securities	1,227,843		(207)	1,227,636
Corporate and other debt securities	2,326,066		(3,492)	2,322,574
	3,553,909		(3,699)	3,550,210
<b>Total</b>	<b>\$ 26,643,408</b>	<b>\$ 6,403</b>	<b>\$ (9,392)</b>	<b>\$ 26,640,419</b>

The contractual maturities of money market funds and marketable securities at June 30, 2015 were as follows:

	<b>Amortized Cost</b>	<b>Fair Value</b>
Due in 1 year or less	\$ 23,153,147	\$ 23,154,820
Due in 1 to 2 years	1,223,276	1,223,468
	<b>\$ 24,376,423</b>	<b>\$ 24,378,288</b>

**Table of Contents****8. Fair Value Measurement**

In determining the fair value of its assets and liabilities, the Company uses various valuation approaches. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access

Level 2 Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly

Level 3 Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement.

The Company's fixed income investments are comprised of obligations of U.S. government agencies and corporate marketable securities. These investments have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. At least annually, the Company validates the prices provided by third party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active. The Company did not adjust or override any fair value measurements provided by the pricing services as of June 30, 2015.

The following fair value hierarchy table presents information about each major category of the Company's assets measured at fair value on a recurring basis as of June 30, 2015:

Fair value measurement at reporting date using:			
Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total

Edgar Filing: REPLIGEN CORP - Form 10-Q

Assets:			
Money market funds	\$ 4,613,256	\$	\$ 4,613,256
U.S. Government and agency securities	8,468,232	4,851,595	13,319,827
Corporate and other debt securities		11,058,461	11,058,461
Total	\$ 13,081,488	\$ 15,910,056	\$ 28,991,544

The Company has no other assets or liabilities for which fair value measurement is either required or has been elected to be applied, other than the liabilities for contingent consideration recorded in connection with the BioFlash Partners, LLC ( BioFlash ) and Refine business combinations. The contingent consideration related to BioFlash is valued using management's estimates of royalties to be paid to the former shareholders of BioFlash based on sales of the acquired assets. The contingent consideration related to the Refine Acquisition is valued using management's estimates of expected future milestone payments based on forecasted sales and a portion of any receipts that might be received in connection with the resolution, withdrawal or settlement of certain patent disputes with a third party to be paid Refine. These valuations are Level 3 valuations as the primary inputs are unobservable.

**Table of Contents**

Changes in the fair value of contingent consideration in the six-month period ended June 30, 2015 are primarily attributable to an increase to the expected Refine milestone payment of \$1,864,000 related to 2015 sales, a \$1,000,000 milestone payment to Refine related to 2014 sales, a \$110,000 minimum royalty payment made to BioFlash, and a final milestone payment to Novozymes Biopharma DK A/S of 25,000 Euros (approximately \$27,700). All milestone payments made in 2015 were previously accrued. The following table provides a rollforward of the fair value of the contingent consideration:

Balance at December 31, 2014	\$ 3,844,574
Payments	(1,137,741)
Changes in fair value	1,879,607
Balance at June 30, 2015	\$ 4,586,440

The following tables provide quantitative information associated with the fair value measurement of the Company's contingent consideration related to Refine using Level 3 inputs:

	Contingent Consideration Refine
Fair value as of June 30, 2015	\$4,185,000
Valuation technique	Probability-adjusted discounted cash flow
Remaining periods in which milestones can be achieved	2015 2016

	Fixed Earn-out	Maximum Variable Earn-out	Accrued Balance
2015	3,500,000	850,000	4,185,000
2016	4,250,000	1,250,000	

The significant unobservable inputs used in the fair value measurement of Refine's contingent consideration are (i) the probabilities of a successful achievement of 2015 and 2016 sales milestones; (ii) the period in which these milestones are expected to be achieved; and (iii) a discount rate. During the first six months of 2015, the estimated fair value of the 2015 contingent payment was increased by \$1,864,000 to \$4,185,000 based upon revised sales forecasts for 2015. Increases or decreases in the Company's projected sales during these periods may result in a significantly higher or lower fair value measurement and could result in a reversal of the current accrual.

There were no remeasurements to fair value during the six months ended June 30, 2015 of financial assets and liabilities that are not measured at fair value on a recurring basis.

**9. Inventories**



Inventories relate to the Company's bioprocessing business. The Company values inventory at cost or, if lower, market value, using the first-in, first-out method. The Company reviews its inventories at least quarterly and records a provision for excess and obsolete inventory based on its estimates of expected sales volume, production capacity and expiration dates of raw materials, work-in-process and finished products. Expected sales volumes are determined based on supply forecasts provided by key customers for the next 3 to 12 months. The Company writes down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected requirements to cost of product revenue. Manufacturing of bioprocessing finished goods is done to order and tested for quality specifications prior to shipment. Reserves for excess and obsolete inventory were approximately \$57,000 at June 30, 2015 and \$78,000 at December 31, 2014.

A change in the estimated timing or amount of demand for the Company's products could result in additional provisions for excess inventory quantities on hand. Any significant unanticipated changes in demand or unexpected quality failures could have a significant impact on the value of inventory and reported operating results. During all periods presented in the accompanying financial statements, there have been no material adjustments related to a revised estimate of inventory valuations.

Work-in-process and finished products inventories consist of material, labor, outside processing costs and manufacturing overhead.

**Table of Contents**

Inventories consist of the following:

	<b>June 30, 2015</b>	<b>December 31, 2014</b>
Raw materials	\$ 8,000,881	\$ 5,373,860
Work-in-process	2,471,586	2,256,265
Finished products	3,833,209	4,753,508
Total	\$ 14,305,676	\$ 12,383,633

**10. Accrued Liabilities**

The Company estimates accrued liabilities by identifying services performed on the Company's behalf, estimating the level of service performed and determining the associated cost incurred for such service as of each balance sheet date. For example, the Company would accrue for professional and consulting fees incurred with law firms, audit and accounting service providers and other third party consultants. These expenses are determined by either requesting those service providers to estimate unbilled services at each reporting date for services incurred or tracking costs incurred by service providers under fixed fee arrangements.

The Company has processes in place to estimate the appropriate amounts to record for accrued liabilities, which principally involve the applicable personnel reviewing the services provided. In the event that the Company does not identify certain costs that have begun to be incurred or the Company under or over-estimates the level of services performed or the costs of such services, the reported expenses for that period may be too low or too high. The date on which certain services commence, the level of services performed on or before a given date, and the cost of such services often require the exercise of judgment. The Company makes these judgments based upon the facts and circumstances known at the date of the financial statements.

Accrued liabilities consist of the following:

	<b>June 30, 2015</b>	<b>December 31, 2014</b>
Employee compensation	\$ 3,040,719	\$ 3,758,511
Taxes	900,799	571,080
Royalty and license fees	1,670,804	
Current portion of contingent consideration	4,323,556	1,135,061
Professional fees	211,288	511,588
Unearned revenue	611,408	129,904
Other accrued expenses	763,743	712,919
Total	\$ 11,522,317	\$ 6,819,063

**11. Commitments and Contingencies**

In March 2014, the Company entered into an amendment of its existing lease to expand the rented space from 55,694 to 75,594 square feet at 41 Seyon Street, Waltham, Massachusetts. Pursuant to the terms of the amended lease, commencing on August 1, 2014 the Company began leasing an additional 19,900 square feet (the Expansion Space ) for a period of eight years and one month. The Expansion Space is a part of the Company's corporate headquarters.

The amended lease provides for additional rent expense of approximately \$361,000 on an annualized basis. Future minimum rental commitments under the amended lease as of June 30, 2015 are as follows:

	<b>Minimum Rental Commitments</b>
2015	\$ 1,178,000
2016	2,355,000
2017	1,895,000
2018	1,435,000
2019	1,371,000
Thereafter	3,728,000

**Table of Contents****12. Income Taxes**

For the three- and six-month periods ended June 30, 2015, the Company had income before taxes of \$4,351,388 and \$8,549,861, respectively. The Company recorded income tax provisions of \$738,831 and \$2,007,817, respectively, for the three- and six-month periods ended June 30, 2015. This results in a year to date effective tax rate of 23.5% for the six-month period ended June 30, 2015. The anticipated movement in the effective tax rate between the interim period and year end is a result of the expected change in the income position in the U.S. The effective income tax rate is based upon the estimated income for the year and the composition of the income in different jurisdictions. The effective tax rate differs from the U.S. statutory tax rate primarily due to the lower statutory tax rate in Sweden.

For the three- and six-month periods ended June 30, 2014, the Company had income before taxes of \$3,243,249 and \$8,641,354, respectively. The Company recorded income tax provisions of \$417,827 and \$1,538,829, respectively, for the three- and six-month periods ended June 30, 2014. This is based on a year to date effective tax rate of 17.8% for the six-month period ended June 30, 2014 and an expected effective tax rate of 24.23% for the year ending December 31, 2014. The anticipated movement in the effective tax rate between the interim period and year end is a result of the expected change in the income position in the U.S. The effective income tax rate is based upon the estimated income for the year and the composition of the income in different jurisdictions. The effective tax rate differs from the U.S. statutory tax rate primarily due to the lower statutory tax rate in Sweden, as well as year-to-date income for the U.S. entity as compared to a projected loss in the U.S. for the full year.

The Company has net operating loss carryforwards of approximately \$43,387,000 and business tax credits carryforwards of approximately \$1,782,000 available to reduce future federal income taxes, if any. The net operating loss and business tax credits carryforwards will continue to expire at various dates through December 2032. Net operating loss carryforwards and available tax credits are subject to review and possible adjustment by the Internal Revenue Service and may be limited in the event of certain changes in the ownership interest of significant stockholders.

As of December 31, 2014, the Company concluded that realization of deferred tax assets beyond December 31, 2014 is not more likely than not, and as such, as of December 31, 2014 it maintained a valuation allowance against the majority of its remaining deferred tax assets. As of June 30, 2015, the Company concluded that realization of deferred tax assets beyond June 30, 2015 is not more likely than not, and as such, as of June 30, 2015 it maintained a valuation allowance against the majority of its remaining deferred tax assets.

The fiscal years ended March 31, 2007 through March 31, 2011 as well as the nine-month fiscal year ended December 31, 2011 and the years ended December 31, 2012, 2013 and 2014 are subject to examination by the Commonwealth of Massachusetts (the Commonwealth) taxing authorities. A corporate excise tax audit was recently completed in the Commonwealth for the fiscal years ended March 31, 2008 through 2011, and the nine-month period ended December 31, 2011. As a result of this audit, the Company has appealed the Commonwealth's position with respect to the March 31, 2008 and 2009 years and has paid \$140,626 to the Commonwealth in July 2015 in respect of assessments for the March 31, 2010, 2011 and December 31, 2011 tax years. The amount paid was previously accrued by the Company. Fiscal years ended December 31, 2012, 2013 and 2014 are subject to examination by other states, U.S. federal and Sweden taxing authorities.

**13. Segment Reporting**

The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one operating segment. As a result, the financial information disclosed herein represents all of the material financial information related to the Company's principal operating segment.

The following table represents the Company's total revenue by geographic area (based on the location of the customer):

	Three months ended June 30,		Six months ended June 30,	
	2015	2014	2015	2014
Sweden	51%	48%	44%	44%
United States	21%	23%	25%	32%
United Kingdom	17%	25%	18%	21%
Other	11%	4%	13%	3%
Total	100%	100%	100%	100%

**Table of Contents**

Revenue from significant customers as a percentage of the Company's total revenue is as follows:

	<b>Three months ended June 30,</b>		<b>Six months ended June 30,</b>	
	<b>2015</b>	<b>2014</b>	<b>2015</b>	<b>2014</b>
GE Healthcare	51%	48%	44%	44%
Bioprocessing Customer B	16%	22%	19%	22%
Bioprocessing Customer C	9%	14%	12%	14%

Significant accounts receivable balances as a percentage of the Company's total trade accounts receivable and other receivables balances are as follows:

	<b>June 30, 2015</b>	<b>December 31, 2014</b>
GE Healthcare	58%	29%

---

**Table of Contents**

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**Overview**

We are a life sciences company that develops, manufactures and markets high-value, bioprocessing products for life sciences and biopharmaceutical companies worldwide. We are a world-leading manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to purify monoclonal antibodies, a type of biologic drug. We also supply several growth factor products and cell filtration products used to increase cell culture productivity during the bioproduction process. In the expanding area of flexible biomanufacturing technologies, we have developed and currently market a series of OPUS® chromatography columns for use in clinical-scale manufacturing. These pre-packed, plug-and-play columns are uniquely customizable to our customers' media and size requirements.

On June 2, 2014, we acquired the business of Refine Technology LLC ( "Refine" ), including Refine's Alternating Tangential Flow ( "ATF" ) System, a market-leading device used to significantly increase product yield during the fermentation step of the biologic drug manufacturing process (the "Refine Business" and the acquisition of the Refine Business, the "Refine Acquisition" ). We purchased all of the assets and assumed certain specified liabilities related to Refine's ATF System. This acquisition strengthened our bioprocessing business by adding a complementary product line while expanding its sales presence worldwide.

We generally manufacture and sell Protein A and growth factors to life sciences companies under supply agreements and sell our chromatography columns, as well as media and quality test kits, and our ATF products directly to biopharmaceutical companies or contract manufacturing organizations or through distributors. We refer to these activities as our bioprocessing business. Our manufacturing facilities are located in the United States and Sweden.

Historically, Repligen also conducted activities aimed at developing proprietary therapeutic drug candidates, often with a potential of entering into a collaboration with a larger commercial stage pharmaceutical or biotechnology company in respect of these programs. As part of our strategic decision in 2012 to focus our efforts on our core bioprocessing business, we reduced our efforts on our clinical development programs and increased our efforts to find collaboration partners to pursue the development and, if successful, the commercialization of these drug programs.

**Critical Accounting Policies and Estimates**

A critical accounting policy is one which is both important to the portrayal of the Company's financial condition and results and requires management's most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. For additional information, please see the discussion of our critical accounting policies in Management's Discussion and Analysis and our significant accounting policies in Note 2 to the Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2014.

**Results of Operations**

***Three months ended June 30, 2015 vs. June 30, 2014***

***Revenues***

Total revenues for the three-month periods ended June 30, 2015 and 2014 were comprised of the following:

	<b>Three months ended June 30,</b>		<b>% Change</b>
	<b>2015</b>	<b>2014</b>	<b>2015 vs. 2014</b>
	<b>(in thousands, except percentages)</b>		
Product revenue	\$ 21,457	\$ 15,551	38%
Total revenue	\$ 21,457	\$ 15,551	38%

Sales of bioprocessing products for the three months ended June 30, 2015 and 2014 were \$21,457,000 and \$15,551,000, respectively, an increase of \$5,906,000, or 38%. This increase was due in part to increases in orders from our key bioprocessing customers. Additionally \$2,812,000 of sales can be attributable to the addition of the Refine Business. Sales of our bioprocessing products can be impacted by the timing of orders, development efforts at our customers or end-users and regulatory approvals for biologics that incorporate our products, which may result in significant quarterly fluctuations. Such quarterly fluctuations are expected, but they may not be predictive of future revenue or otherwise indicate a trend.



**Table of Contents***Costs and operating expenses*

Total costs and operating expenses for the three-month periods ended June 30, 2015 and 2014 were comprised of the following:

	<b>Three months ended June 30,</b>		<b>% Change</b>
	<b>2015</b>	<b>2014</b>	<b>2015 vs. 2014</b>
	<b>(in thousands, except percentages)</b>		
Cost of product revenue	\$ 8,586	\$ 6,672	29%
Research and development	1,252	1,430	(12%)
Selling, general and administrative	6,242	4,325	44%
Contingent consideration fair value adjustments	769	18	4,172%
<b>Total costs and operating expenses</b>	<b>\$ 16,849</b>	<b>\$ 12,445</b>	<b>35%</b>

Cost of product revenue was approximately \$8,586,000 and \$6,672,000 for the three-month periods ended June 30, 2015 and 2014, respectively, an increase of \$1,914,000 or 29%. This increase is primarily due to the increased product revenue noted above and the addition of the Refine Business. Gross margins may decline over the remainder of 2015 based on expected production volume and shipments and product mix.

Research and development expenses were approximately \$1,252,000 and \$1,430,000 for the three-month periods ended June 30, 2015 and 2014, respectively, a decrease of \$178,000 or 12%. This decrease is primarily related to the timing of bioprocessing product development which included supplies and other development expenses related to our new products in development.

Selling, general and administrative expenses were approximately \$6,242,000 and \$4,325,000 for the three-month periods ended June 30, 2015 and 2014, respectively, an increase of \$1,917,000 or 44%. This increase is primarily due to higher administrative expenses related to the planned implementation and training of an inventory accounting software package, the buildout of our administrative infrastructure to support future growth and the expansion of our customer-facing activities to drive sales of our bioprocessing products.

*Contingent Consideration*

Contingent consideration fair value adjustments were approximately \$769,000 and \$18,000 for the three-month periods ended June 30, 2015 and 2014, respectively, an increase of \$751,000. The increase in the fair value adjustment during the second quarter of 2015 relates to the increased probability of achieving the 2015 Refine sales milestone.

*Investment income*

Investment income includes income earned on invested cash balances. Investment income was approximately \$19,000 and \$85,000 for the three-month periods ended June 30, 2015 and 2014, respectively. This decrease of \$66,000, or 78%, is primarily attributable to lower average invested cash balances.

*Other income (expense)*

Other income (expense) was approximately (\$269,000) and \$65,000 for the three-month periods ended June 30, 2015 and 2014, respectively, and was primarily attributable to foreign currency (losses) and gains related to our Sweden operations.

*Provision for income taxes*

For the three months ended June 30, 2015, we had income before taxes of approximately \$4,351,000 and recorded a tax provision of approximately \$739,000 for an effective tax rate of approximately 17%. The effective tax rate differs from the U.S. statutory tax rate primarily due to the lower statutory tax rate in Sweden.

**Table of Contents*****Six months ended June 30, 2015 vs. June 30, 2014******Revenues***

Total revenues for the six-month periods ended June 30, 2015 and 2014 were comprised of the following:

	<b>Six months ended June 30,</b>		<b>% Change</b>
	<b>2015</b>	<b>2014</b>	<b>2015 vs. 2014</b>
	<b>(in thousands, except percentages)</b>		
Product revenue	\$ 42,274	\$ 29,886	41%
Royalty and other revenue		1,991	-100%
<b>Total revenue</b>	<b>\$ 42,274</b>	<b>\$ 31,877</b>	<b>33%</b>

Sales of bioprocessing products for the six-month periods ended June 30, 2015 and 2014 were \$42,274,000 and \$29,886,000, respectively, an increase of \$12,388,000, or 41%. This increase was due in part to increases in orders from our key bioprocessing customers. Additionally, \$5,394,000 of this increase is attributable to the addition of the Refine Business. Sales of our bioprocessing products are impacted by the timing of orders, development efforts at our customers or end-users and regulatory approvals for biologics that incorporate our products, which may result in significant quarterly fluctuations. Such quarterly fluctuations are expected, but they may not be predictive of future revenue or otherwise indicate a trend.

During the six months ended June 30, 2014, we also recognized \$1,991,000 of revenue under the Asset Purchase Agreement with BioMarin Pharmaceutical Inc. ( BioMarin ) to advance Repligen's histone deacetylase inhibitor (HDACi) portfolio.

***Costs and operating expenses***

Total costs and operating expenses for the six-month periods ended June 30, 2015 and 2014 were comprised of the following:

	<b>Six months ended June 30,</b>		<b>% Change</b>
	<b>2015</b>	<b>2014</b>	<b>2015 vs. 2014</b>
	<b>(in thousands, except percentages)</b>		
Cost of product revenue	\$ 16,659	\$ 13,007	28%
Research and development	2,819	2,631	7%
Selling, general and administrative	12,267	7,709	59%
Contingent consideration fair value adjustments	1,881	116	1,522%
<b>Total costs and operating expenses</b>	<b>\$ 33,626</b>	<b>\$ 23,463</b>	<b>43%</b>

Cost of product revenue was approximately \$16,659,000 and \$13,007,000 for the six-month periods ended June 30, 2015 and 2014, respectively, an increase of \$3,652,000 or 28%. This increase is primarily due to the increased product revenue noted above and the addition of the Refine Business. Gross margins may decline over the remainder of 2015 based on expected production volume and shipments and product mix.

Research and development expenses were approximately \$2,819,000 and \$2,631,000 for the six-month periods ended June 30, 2015 and 2014, respectively, an increase of \$188,000 or 7%. This increase is primarily related to bioprocessing product development which included increased personnel, supplies and other development expenses related to our new products in development.

Selling, general and administrative expenses were approximately \$12,267,000 and \$7,709,000 for the six-month periods ended June 30, 2015 and 2014, respectively, an increase of \$4,558,000 or 59%. This increase is primarily due to higher administrative expenses related to the planned implementation and training of an inventory accounting software package, the buildout of our administrative infrastructure to support future growth and the expansion of our customer-facing activities to drive sales of our bioprocessing products.

#### *Contingent Consideration*

Contingent consideration fair value adjustments were approximately \$1,881,000 and \$116,000 for the six-month periods ended June 30, 2015 and 2014, respectively, an increase of \$1,765,000. The increase in the fair value adjustment during 2015 relates to the increased probability of achieving the 2015 Refine sales milestone.

---

**Table of Contents**

*Investment income*

Investment income includes income earned on invested cash balances. Investment income was approximately \$56,000 and \$187,000 for the six-month periods ended June 30, 2015 and 2014, respectively. This decrease of \$131,000, or 70%, is primarily attributable to lower average invested cash balances.

*Other income (expense)*

Other income (expense) was approximately (\$137,000) and \$68,000 for the six-month periods ended June 30, 2015 and 2014, respectively, and was primarily attributable to foreign currency (losses) and gains related to our Sweden operations.

*Provision for income taxes*

For the six months ended June 30, 2015, we had income before taxes of approximately \$8,550,000 and recorded a tax provision of approximately \$2,008,000 for an effective tax rate of approximately 23.5%. The effective tax rate differs from the U.S. statutory tax rate primarily due to the lower statutory tax rate in Sweden.

**Liquidity and capital resources**

We have financed our operations primarily through revenues derived from product sales and research grants, as well as proceeds and royalties from license arrangements and a litigation settlement and sales of equity securities. Our revenue for the foreseeable future will primarily be limited to our bioprocessing product revenue.

At June 30, 2015, we had cash and marketable securities of \$64,390,000 compared to \$62,003,000 at December 31, 2014. A deposit for leased office space of \$450,000 is classified as restricted cash and is not included in cash and marketable securities totals as of June 30, 2015 or December 31, 2014.

*Operating activities*

For the six-month period ended June 30, 2015, our operating activities provided cash of \$5,113,000, reflecting net income of \$6,542,000 and non-cash charges totaling \$6,070,000 mainly attributable to depreciation and amortization, stock-based compensation charges and the revaluation of contingent consideration. An increase in accounts receivable consumed \$6,853,000 of cash, and was primarily due to a 41% increase in product revenues as well as timing of sales and payments from customers. The remaining cash flow used in operations resulted from net unfavorable changes in various other working capital accounts.

For the six-month period ended June 30, 2014, our operating activities provided cash of \$10,320,000, reflecting net income of \$7,103,000 and non-cash charges totaling \$2,978,000 mainly attributable to depreciation and amortization, stock-based compensation charges, deferred tax expense and the revaluation of contingent consideration. The remaining cash flow provided by operations resulted from net favorable changes in various working capital accounts, in particular the collection of the final Orenica royalty from Bristol Myers of \$4.9 million and the tenant improvement allowance of \$1,800,000 from our landlord.

*Investing activities*

We place our marketable security investments in high quality credit instruments as specified in our investment policy guidelines. Our investing activities provided \$503,000 for the six-month period ended June 30, 2015, primarily due to

net redemptions of marketable securities of \$2,240,000 offset by \$1,737,000 used for fixed asset additions. Our investing activities consumed \$16,853,000 for the six-month period ended June 30, 2014, primarily due to the Refine Acquisition, fixed asset additions and an increase in restricted cash, partially offset by net redemptions of marketable debt securities.

*Financing activities*

For the six-month periods ended June 30, 2015 and 2014, our financing activities provided cash of \$587,000 and \$1,338,000, respectively. For the six-month period ended June 30, 2015, proceeds from exercises of \$686,000 were partially offset by contingent consideration payments of \$99,000 which stemmed from the initial valuation of the likelihood that the 2014 ATF sales milestone would be achieved. For the six-month period ended June 30, 2014, cash proceeds from exercises were \$1,338,000.

We do not currently use derivative financial instruments.

Working capital increased by \$7,179,000 to \$77,442,000 at June 30, 2015 from \$70,263,000 at December 31, 2014 due to the various changes noted above.

**Table of Contents**

Our future capital requirements will depend on many factors, including the following:

the expansion of our bioprocessing business;

the ability to sustain sales and profits of our bioprocessing products;

market acceptance of our new products;

our ability to acquire additional bioprocessing products;

the resources required to successfully integrate the Refine Acquisition and recognize expected synergies;

our ability to realize value from our outlicensed early stage programs, CNS and RG1068;

the scope of and progress made in our research and development activities;

the extent of any share repurchase activity; and

the success of any proposed financing efforts.

Absent acquisitions of additional products, product candidates or intellectual property, we believe our current cash balances are adequate to meet our cash needs for at least the next 24 months. We expect operating expenses in the year ending December 31, 2015 to increase as we continue to expand our bioprocessing business. We expect to incur continued spending related to the development and expansion of our bioprocessing product lines and expansion of our commercial capabilities for the foreseeable future. Our future capital requirements may include, but are not limited to, purchases of property, plant and equipment, the acquisition of additional bioprocessing products and technologies to complement our existing manufacturing capabilities, and continued investment in our intellectual property portfolio.

We plan to continue to invest in our bioprocessing business and in key research and development activities associated with the development of new bioprocessing products. We actively evaluate various strategic transactions on an ongoing basis, including monetizing existing assets and licensing or acquiring complementary products, technologies or businesses that would complement our existing portfolio of development programs. We continue to seek to acquire such potential assets that may offer us the best opportunity to create value for our shareholders. In order to acquire such assets, we may need to seek additional financing to fund these investments. This may require the issuance or sale of additional equity or debt securities. The sale of additional equity may result in additional dilution to our stockholders. Should we need to secure additional financing to acquire a product, fund future investment in research and development, or meet our future liquidity requirements, we may not be able to secure such financing, or obtain such financing on favorable terms because of the volatile nature of the biotechnology marketplace.

**Off-Balance Sheet Arrangements**

We do not have any special purpose entities or off-balance sheet financing arrangements as of June 30, 2015.

**Contractual obligations**

As of June 30, 2015, we had the following fixed obligations and commitments:

(In thousands)	Total	Payments Due by Period			
		Less than 1 Year	1 - 3 Years	3 - 5 Years	More than 5 Years
Operating lease obligations	\$ 13,187	\$ 2,355	\$ 4,250	\$ 2,854	\$ 3,728
Purchase obligations <sup>(1)</sup>	6,739	6,739			
Contingent consideration <sup>(2)</sup>	4,586	4,315	271		
Total	\$ 24,512	\$ 13,409	\$ 4,521	\$ 2,854	\$ 3,728

(1) Primarily represents purchase orders for the procurement of raw material for manufacturing.

(2) Represents the current estimated fair value of contingent consideration amounts relating to acquisitions. These amounts are recorded in accrued expenses and long term liabilities on our consolidated balance sheets.

**Cautionary Statement Regarding Forward-Looking Statements**

This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). The forward-looking statements in this Quarterly Report on Form 10-Q do not constitute guarantees of future



**Table of Contents**

performance. Investors are cautioned that statements in this Quarterly Report on Form 10-Q which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding current or future financial performance and position, potential impairment of future earnings, management's strategy, plans and objectives for future operations or acquisitions, product development and sales, litigation strategy, product candidate research, development and regulatory approval, selling, general and administrative expenditures, intellectual property, development and manufacturing plans, availability of materials and product and adequacy of capital resources and financing plans constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative or supply relationships, including our agreement with BioMarin, our ability to successfully negotiate and consummate development and commercialization partnerships for our portfolio of therapeutic and diagnostic assets on acceptable terms, if at all, our ability to successfully grow our bioprocessing business, including as a result of acquisition, commercialization or partnership opportunities, the success of our clinical trials and our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our patent and other intellectual property rights, the risk of litigation with collaborative partners, our limited sales and marketing experience and capabilities, our limited manufacturing capabilities and our dependence on third-party manufacturers and value-added resellers, our ability to hire and retain skilled personnel, the market acceptance of our products, reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition, our ability to compete with larger, better financed pharmaceutical and biotechnology companies that may develop new approaches to the treatment of our targeted diseases, our history of losses and expectation of incurring losses, our ability to generate future revenues, our ability to successfully integrate Repligen Sweden and Refine, our ability to raise additional capital to continue our drug development programs or fund potential acquisitions, our volatile stock price, the effects of our anti-takeover provisions, and the impact of the expiration on December 31, 2013 of Bristol-Myers Squibb royalty payments based on its U.S. sales of Orenicia®. Further information on potential risk factors that could affect our financial results are included in the filings made by us from time to time with the Securities and Exchange Commission including under the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2014.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK****Interest rate risk**

We have investments in commercial paper, U.S. Government and agency securities as well as corporate bonds and other debt securities. As a result, we are exposed to potential loss from market risks that may occur as a result of changes in interest rates, changes in credit quality of the issuer or otherwise.

We generally place our marketable security investments in high quality credit instruments, as specified in our investment policy guidelines. A hypothetical 100 basis point decrease in interest rates would result in an approximate \$117,000 decrease in the fair value of our investments as of June 30, 2015. We believe, however, that the conservative nature of our investments mitigates our interest rate exposure, and our investment policy limits the amount of our credit exposure to any one issue, issuer (with the exception of U.S. agency obligations) and type of instrument. We do not expect any material loss from our marketable security investments and therefore believe that our potential interest rate exposure is limited.

**Foreign exchange risk**

Transactions by our subsidiary, Repligen Sweden, may be denominated in Swedish kronor, British pound sterling, U.S. dollars, or in Euros while the entity's functional currency is the Swedish krona. Certain sales transactions related to ATF system products are denominated in foreign currencies. Exchange gains or losses resulting from the translation between the transactional currency and the functional currency of Repligen Sweden and ATF system product sales are included in our consolidated statements of comprehensive income. The functional currency of the Company is U.S. dollars. Fluctuations in exchange rates may adversely affect our results of operations, financial position and cash flows. We currently do not seek to hedge this exposure to fluctuations in exchange rates.

#### **ITEM 4. CONTROLS AND PROCEDURES**

##### **Disclosure Controls and Procedures**

The Company's management, with the participation of the principal executive officer and the principal financial officer, has evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this report. Based on such evaluation, the principal executive officer and principal financial officer have concluded that, as of the end of such period, the

**Table of Contents**

Company's disclosure controls and procedures were effective in ensuring that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, on a timely basis, and is accumulated and communicated to the Company's management, including the Company's principal executive officer and the Company's principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

**Changes in Internal Control**

There was no change in the Company's internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

**Table of Contents**

**PART II. OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

**ITEM 1A. RISK FACTORS**

The matters discussed in this Quarterly Report on Form 10-Q include forward-looking statements that involve risks or uncertainties. These statements are neither promises nor guarantees, but are based on various assumptions by management regarding future circumstances, over many of which Repligen has little or no control. A number of important risks and uncertainties, including those identified under the caption **Risk Factors** in Item 1A in our Annual Report on Form 10-K for the year ended December 31, 2014 and subsequent filings as well as risks and uncertainties discussed elsewhere in this Quarterly Report on Form 10-Q, could cause our actual results to differ materially from those in the forward-looking statements.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

In June 2008, the Board of Directors authorized a program to repurchase up to 1.25 million shares of our common stock to be repurchased at the discretion of management from time to time in the open market or through privately negotiated transactions. The repurchase program has no set expiration date and may be suspended or discontinued at any time. We did not repurchase any shares of common stock during the three- and six-month periods ended June 30, 2015. As of June 30, 2015, there are 657,173 shares remaining under this authorization.

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM 4. MINE SAFETY DISCLOSURES**

Not applicable.

**ITEM 5. OTHER INFORMATION**

None.

**Table of Contents**

**ITEM 6. EXHIBITS**

**(a) Exhibits**

**Exhibit**

<b>Number</b>	<b>Document Description</b>
3.1	Restated Certificate of Incorporation, dated June 30, 1992 and amended September 17, 1999 (filed as Exhibit 3.1 to Repligen Corporation's Quarterly Report on Form 10-Q for the quarter ended September 30, 1999 and incorporated herein by reference). (File No. 000-14656)
3.2	Amended and Restated By-Laws (filed as Exhibit 3.2 to Repligen Corporation's Quarterly Report on Form 10-Q for the quarter ended September 30, 2003 and incorporated herein by reference). (File No. 000-14656)
3.3	Amendment No. 1 to the Amended and Restated By-Laws (filed as Exhibit 3.1 to Repligen Corporation's Current Report on Form 8-K filed on December 20, 2011 and incorporated herein by reference).
3.4	Amendment No. 2 to the Amended and Restated By-Laws (filed as Exhibit 3.1 to Repligen Corporation's Current Report on Form 8-K filed on May 25, 2012 and incorporated herein by reference).
3.5	Certificate of Amendment to the Certificate of Incorporation of Repligen Corporation, effective as of May 16, 2014 (filed as Exhibit 3.1 to Repligen Corporation's Current Report on Form 8-K filed on May 19, 2014 and incorporated herein by reference).
10.1 +	Repligen Corporation Amended and Restated Non-Employee Directors' Compensation Policy
31.1 +	Rule 13a-14(a)/15d-14(a) Certification.
31.2 +	Rule 13a-14(a)/15d-14(a) Certification.
32.1 *	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101+	The following materials from Repligen Corporation on Form 10-Q for the quarterly period ended June 30, 2015, formatted in Extensible Business Reporting Language (xBRL): (i) Condensed Consolidated Statements of Comprehensive Income (Loss), (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statements of Cash Flows, and (iv) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text.

+ Filed herewith.

\* Furnished herewith.

Table of Contents

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

REPLIGEN CORPORATION

Date: August 6, 2015

By: /s/ TONY J. HUNT  
**Tony J. Hunt**  
**President and Chief Executive Officer**  
**(Principal executive officer)**  
**Repligen Corporation**

Date: August 6, 2015

By: /s/ JON SNODGRES  
**Jon Snodgres**  
**Chief Financial Officer**  
**(Principal financial officer)**  
**Repligen Corporation**